A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer

被引:0
作者
Yusuke Sasaki
Satoru Iwasa
Shunsuke Okazaki
Masahiro Goto
Yasushi Kojima
Atsushi Naganuma
Kengo Nagashima
Yushi Nagai
Hidekazu Hirano
Yoshitaka Honma
Atsuo Takashima
Ken Kato
Tetsuya Hamaguchi
机构
[1] National Cancer Center Hospital,Gastrointestinal Medical Oncology Division
[2] National Hospital Organization Kyoto Medical Center,Medical Oncology Division
[3] Osaka Medical College Hospital,Cancer Chemotherapy Center
[4] National Center for Global Health and Medicine,Department of Gastroenterology
[5] National Hospital Organization Takasaki General Medical Center,Department of Gastroenterology
[6] Chiba University Graduate School of Medicine,Department of Global Clinical Research
[7] National Cancer Center Hospital,Clinical Trial Support Office
来源
Gastric Cancer | 2018年 / 21卷
关键词
Cisplatin; Elderly patient; Gastric cancer; S-1;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:439 / 445
页数:6
相关论文
共 77 条
[1]  
Murad AM(1993)Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer (Phila) 72 37-41
[2]  
Santiago FF(1994)Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189-190
[3]  
Petroianu A(1995)Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with alone in patients with non-resectable gastric cancer Br J Cancer 71 587-591
[4]  
Rocha PR(2009)Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1063-1069
[5]  
Rodrigues MA(2010)Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial J Clin Oncol 28 1547-1553
[6]  
Rausch M(2008)S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215-221
[7]  
Glimelius B(2008)A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer Br J Cancer 99 584-590
[8]  
Hoffman K(2010)Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo cooperative oncology group study Cancer Chemother Pharmacol 65 1093-1099
[9]  
Haglund U(2007)International society of geriatric oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency Eur J Cancer 43 14-34
[10]  
Nyrén O(1982)A confidence interval for the median survival time Biometrics 38 29-41